Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Wells Fargo Upgrades Bicara Therapeutics to Equal-Weight, Maintains Price Target to $8

Author: Benzinga Newsdesk | May 23, 2025 02:11pm
Wells Fargo analyst Eva Fortea Verdejo upgrades Bicara Therapeutics (NASDAQ:BCAX) from Underweight to Equal-Weight and maintains the price target from $8 to $8.

Posted In: BCAX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist